ResMed vs Bristol Myers Squibb

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (76 vs 80)
ResMed logo

ResMed

LeaderHealthcare Tech

Sleep & Respiratory Devices

ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.

AI VisibilityBeta
Overall Score
B76
Category Rank
#71 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
75
Gemini
71

About

ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.

Full profile
Bristol Myers Squibb logo

Bristol Myers Squibb

LeaderHealthcare Tech

Enterprise

Princeton NJ biopharma (NYSE: BMY) at $48.3B 2024 revenue; Eliquis $13.3B, Opdivo $9.2B, Cobenfy schizophrenia launch; $23B acquisitions (Karuna+Mirati+RayzeBio) building next pipeline vs. Pfizer and Merck.

AI VisibilityBeta
Overall Score
A80
Category Rank
#18 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
78
Perplexity
78
Gemini
80

About

Bristol Myers Squibb (BMS) is a Princeton, New Jersey-based global biopharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: BMY) as an S&P 500 Healthcare component — discovering, developing, and delivering innovative medicines for serious diseases including cancer, cardiovascular disease, immunology, and neuroscience through approximately 34,000 employees worldwide. In fiscal year 2024, BMS reported total revenue of $48.3 billion (+7% year-over-year), with its Growth Portfolio generating $22.6 billion (+17%), driven by blockbusters Eliquis ($13.3B anticoagulant), Opdivo ($9.2B immuno-oncology), and Revlimid ($5.8B multiple myeloma). New product revenue surged 77% to $3.6 billion, led by schizophrenia treatment Cobenfy (formerly KarXT), CAR-T therapy Breyanzi, anemia drug Reblozyl, and Opdualag checkpoint inhibitor combination. CEO Dr. Christopher Boerner assumed leadership in November 2023, accelerating BMS's pipeline expansion through three transformative acquisitions in 2024: Karuna Therapeutics ($14B, Cobenfy/KarXT for schizophrenia and Alzheimer's agitation), Mirati Therapeutics ($4.8B, KRAS-targeted oncology), and RayzeBio ($4.1B, radiopharmaceutical cancer therapy).

Full profile

AI Visibility Head-to-Head

76
Overall Score
80
#71
Category Rank
#18
83
AI Consensus
83
stable
Trend
stable
72
ChatGPT
78
75
Perplexity
78
71
Gemini
80
77
Claude
84
77
Grok
77

Key Details

Category
Sleep & Respiratory Devices
Enterprise
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only ResMed
Sleep & Respiratory Devices

Integrations

Only Bristol Myers Squibb
ResMed is classified as company. Bristol Myers Squibb is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.